SQLite Web: event_store.db

Update row 39793 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-14T02:04:49.876253+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:15d20606cd9bf409","evidence_event_ids":["evt_3838374233fc"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1628171/0001193125-26-152039.txt","as_of":"2026-04-14T02:04:49.876253+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1628171/0001193125-26-152039.txt","company":"Revolution Medicines, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1628171/0001193125-26-152039.txt","article_chars":4829,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_52a24e3c5d1e46dd","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1628171/0001193125-26-152039.txt","content_type":"text/plain","enriched_at":"2026-04-14T02:38:59.252490+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"8-K","final_url":"https://www.sec.gov/Archives/edgar/data/1628171/0001193125-26-152039.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1628171/0001193125-26-152039.txt","source_event_id":"evt_3838374233fc","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"7cabf5a395bb41f7","kind":"sec_filing","published_at":"20260413","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.74,"dates_mentioned":["2026-04-13","2026-04-14","2026-02-25"],"entities":[{"asset_class":"equity","name":"Revolution Medicines, Inc.","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"other","name":"daraxonrasib","relevance":"high","symbol":"","type":"drug"},{"asset_class":"other","name":"RASolute 302","relevance":"high","symbol":"","type":"clinical_trial"},{"asset_class":"other","name":"U.S. Food and Drug Administration","relevance":"medium","symbol":"","type":"regulator"},{"asset_class":"other","name":"Commissioner\u2019s National Priority Voucher","relevance":"medium","symbol":"","type":"regulatory_program"}],"event_type":"earnings","information_gaps":["The specific Form 8-K item(s) and exhibit details are not present in the provided cleaned text (material_items empty).","PFS numeric results (e.g., median PFS, hazard ratio, p-value) are not included in the provided text.","The exact definition of \u201cfirst interim analysis\u201d and whether any prior interim results were previously disclosed is not provided.","No financial guidance or monetary figures are disclosed in the provided text; the filing appears to be clinical-trial update oriented rather than earnings guidance.","No prior known state is included in the prompt, so the exact delta versus prior disclosures cannot be determined from provided text alone."],"key_facts":["Form 8-K filed by Revolution Medicines, Inc. with a report date of April 13, 2026.","On April 13, 2026, the company shared topline results from its global, randomized, controlled Phase 3 RASolute 302 trial evaluating daraxonrasib in metastatic pancreatic ductal adenocarcinoma patients previously treated.","Daraxonrasib was administered orally once daily; comparator was standard-of-care cytotoxic chemotherapy delivered intravenously.","In the overall (intent-to-treat) population, median OS was 13.2 months for daraxonrasib versus 6.7 months for chemotherapy.","The OS hazard ratio was 0.40 with p < 0.0001.","The company stated statistically significant and clinically meaningful improvements in both PFS and OS versus standard of care.","The company stated daraxonrasib was generally well tolerated with a manageable safety profile and no new safety signals.","Based on the first interim analysis, all PFS and OS endpoint results are considered final.","The company intends to submit the data to global regulatory authorities, including the FDA, as part of a future New Drug Application under a Commissioner\u2019s National Priority Voucher."],"numeric_claims":[{"label":"median OS (daraxonrasib, months)","value":"13.2"},{"label":"median OS (chemotherapy, months)","value":"6.7"},{"label":"OS hazard ratio","value":"0.40"},{"label":"OS p-value","value":"< 0.0001"}],"primary_claim":"In the Phase 3 RASolute 302 intent-to-treat population, daraxonrasib showed a median OS of 13.2 months versus 6.7 months for chemotherapy (hazard ratio 0.40, p < 0.0001), with generally well-tolerated safety and no new safety signals.","relevance_score":0.78,"sentiment":"positive","source_quality":"high","summary":"Revolution Medicines, Inc. filed a Form 8-K on April 13, 2026 announcing topline results from its Phase 3 RASolute 302 trial of daraxonrasib in metastatic pancreatic ductal adenocarcinoma. The company reported statistically significant improvements in PFS and OS versus standard-of-care chemotherapy and stated no new safety signals at this interim analysis.","topics":["SEC filing","Form 8-K","Phase 3 clinical trial topline results","metastatic pancreatic ductal adenocarcinoma","daraxonrasib","progression-free survival","overall survival","hazard ratio","safety/tolerability","regulatory submission plans","New Drug Application"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Revolution Medicines, Inc. \u00b7 Filed 20260413","ticker":"RVMDW","tickers":["RVMDW"],"title":"RVMDW filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1628171/0001193125-26-152039.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel